1093211-84-7

Basic information

• Product Name: phenyl N-(1,2-benzoxazol-3-yl)carbamate
• Synonyms: phenyl N-(1,2-benzoxazol-3-yl)carbamate
• CAS NO: 1093211-84-7
• Molecular Weight: 254.245
• Mol File: 1093211-84-7.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: phenyl N-(1,2-benzoxazol-3-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: phenyl N-(1,2-benzoxazol-3-yl)carbamate(1093211-84-7)
• EPA Substance Registry System: phenyl N-(1,2-benzoxazol-3-yl)carbamate(1093211-84-7)

Safety Data

• Hazardous Substances Data: 1093211-84-7(Hazardous Substances Data)

Upstream product

• 36216-80-5 3-amino-1,2-benzisoxazole 
• 1885-14-9 phenyl chloroformate 

Downstream Products

• 1257882-22-6 C₂₇H₂₆ClN₅O₃ 
• 1257881-96-1 7-[3-(4-chloro-phenoxy)-benzyl]-2,7-diaza-spiro[3.5]nonane-2-carboxylic acid benzo[d]isoxazol-3-ylamide 
• 1257881-63-2 2-[3-(4-chloro-phenoxy)-benzyl]-2,7-diaza-spiro[3.5]nonane-7-carboxylic acid benzo[d]isoxazol-3-ylamide 
• 1093209-18-7 C₂₅H₂₃ClN₄O₃ 
• 1093209-19-8 4-[3-(4-chloro-phenoxy)-benzyl]-piperazine-1-carboxylic acid benzo[d]isoxazol-3-ylamide trifluoroacetate 

Relevant articles and documents

THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES

A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4- position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseasesand malaria; and organ and cell transplant rejection.

HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE

Certain heteroaryl-substituted spirocyclic diamine urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).

7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS

Provided herein are 7-azaspiro[3.5]nonane-7-carboxamide compounds and the pharmaceutically acceptable salts of such compounds useful in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity, conditions including including acute pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, cancer and cancer pain, fibromyalgia, rheumatoid arthritis, inflammatory bowel disease, lupus, diabetes, allergic asthma, vascular inflammation, urinary incontinence, overactive bladder, emesis, cognitive disorders, anxiety, depression, sleeping disorders, eating disorders, movement disorders, glaucoma, psoriasis, multiple sclerosis, cerebrovascular disorders, brain injury, gastrointestinal disorders, hypertension, or cardiovascular disease